

ADA Antibody (C-term)
Mouse Monoclonal Antibody (Mab)
Catalog # AW5620**Specification**

ADA Antibody (C-term) - Product Information

Application	WB,E
Primary Accession	P00813
Reactivity	Human
Host	Mouse
Clonality	Monoclonal
Calculated MW	H=41 KDa
Isotype	IgG1,k
Antigen Source	HUMAN

ADA Antibody (C-term) - Additional Information**Gene ID** 100**Antigen Region**
287-314**Other Names**

Adenosine deaminase, Adenosine aminohydrolase, ADA, ADA1

Dilution

WB~~1:4000

Target/Specificity

This ADA antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 287-314 amino acids from the C-terminal region of human ADA.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

ADA Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

ADA Antibody (C-term) - Protein Information**Name** ADA**Synonyms** ADA1**Function**

Catalyzes the hydrolytic deamination of adenosine and 2- deoxyadenosine (PubMed:<a

<http://www.uniprot.org/citations/16670267> target="_blank">16670267, PubMed:23193172, PubMed:26166670, PubMed:8452534, PubMed:9361033). Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4 (PubMed:20959412). Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion (PubMed:11772392). Enhances dendritic cell immunogenicity by affecting dendritic cell costimulatory molecule expression and cytokines and chemokines secretion (By similarity). Enhances CD4+ T-cell differentiation and proliferation (PubMed:20959412). Acts as a positive modulator of adenosine receptors ADORA1 and ADORA2A, by enhancing their ligand affinity via conformational change (PubMed:23193172). Stimulates plasminogen activation (PubMed:15016824). Plays a role in male fertility (PubMed:21919946, PubMed:26166670). Plays a protective role in early postimplantation embryonic development (By similarity). Also responsible for the deamination of cordycepin (3'-deoxyadenosine), a fungal natural product that shows antitumor, antibacterial, antifungal, antiviral, and immune regulation properties (PubMed:26038697).

Cellular Location

Cell membrane; Peripheral membrane protein; Extracellular side. Cell junction. Cytoplasmic vesicle lumen {ECO:0000250|UniProtKB:P03958}. Cytoplasm. Lysosome. Note=Colocalized with DPP4 at the cell surface.

Tissue Location

Found in all tissues, occurs in large amounts in T- lymphocytes (PubMed:20959412). Expressed at the time of weaning in gastrointestinal tissues.


ADA Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

ADA Antibody (C-term) - Images





All lanes : Anti-ADA Antibody (C-term) at 1:4000 dilution Lane 1: Jurkat whole cell lysate Lane 2: MOLT-4 whole cell lysate Lane 3: CCRF-CEM whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-mouse IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 41 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

ADA Antibody (C-term) - Background

This gene encodes an enzyme that catalyzes the hydrolysis of adenosine to inosine. Various mutations have been described for this gene and have been linked to human diseases. Deficiency in this enzyme causes a form of severe combined immunodeficiency disease (SCID), in which there is dysfunction of both B and T lymphocytes with impaired cellular immunity and decreased production of immunoglobulins, whereas elevated levels of this enzyme have been associated with congenital hemolytic anemia.

ADA Antibody (C-term) - References

- Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)
- Gloria-Bottini, F., et al. Am. J. Med. Sci. 340(2):103-108(2010)
- Levine, A.J., et al. Cancer Epidemiol. Biomarkers Prev. 19(7):1812-1821(2010)
- Spina, C., et al. Cancer Invest. (2010) In press :
- Ri, G., et al. Anticancer Res. 30(6):2347-2349(2010)